# Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level

> **NCT07649525** · PHASE3 · RECRUITING · sponsor: **University of Leeds** · enrollment: 1226 (estimated)

## Conditions studied

- Multiple Myeloma (MM)
- Plasma Cell Leukemia (PCL)

## Interventions

- **DRUG:** Daratumumab
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Teclistamab
- **DRUG:** Talquetamab

## Key facts

- **NCT ID:** NCT07649525
- **Lead sponsor:** University of Leeds
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2033-06
- **Final completion:** 2037-06
- **Target enrollment:** 1226 (ESTIMATED)
- **Last updated:** 2026-07-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07649525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07649525, "Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07649525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*